[ A21-164] Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 07.07.2022
Project no.:
A21-164
Commission:
Commission awarded on 14.12.2021 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with advanced or recurrent endometrial cancer whose disease has progressed during or after prior platinum-based therapy at any stage of the disease when surgery or radiation to cure the cancer is not an option for them
- Patients for whom doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: indication of a considerable added benefit
- Patients for whom a therapy option other than doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-04-19.
Federal Joint Committee (G-BA)
2022-07-07 A G-BA decision was published.
G-BA documents on this decision